CalciMedica, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
CalciMedica, Inc. (CALC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.56% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-11
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.50%, a 10.76% increase year-over-year.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 3.16%, a 7.48% increase year-over-year.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 2.94%, a 17.42% decline year-over-year.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.56%.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.50%, a 11.11% increase from fiscal 2024.
- CalciMedica, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.15%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.56% 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 3.50% 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 3.50% 10-K · filed 2026-03-03 | |||
| 2025-09-30 | 3.50% 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 3.49% 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 3.16% 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 3.15% 10-K · filed 2026-03-03 | |||
| 2024-09-30 | 3.11% 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 2.96% 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 2.94% 10-Q · filed 2025-05-14 | |||
| 2023-03-31 | 3.56% 10-Q · filed 2024-05-13 | |||
| 2022-09-30 | 3.28% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 2.80% 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |